Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences, Inc. (Nasdaq: CSTL) presented data on its skin cancer gene expression profile tests during the 57th Meeting of The American Society of Dermatopathology. The DecisionDx®-Melanoma test was highlighted for its ability to predict sentinel lymph node (SLN) metastasis using tumor biology, demonstrating significant predictive power (p<0.001). Additionally, the new DecisionDx® DiffDx™-Melanoma test could aid in diagnosing unclear melanocytic lesions, boasting a 99.1% sensitivity and 94.3% specificity. These advancements may enhance treatment decisions and patient management in skin cancer.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced the commercial availability of DecisionDx® DiffDx™-Melanoma, a diagnostic test designed to assist dermatopathologists in evaluating suspicious pigmented lesions. This gene expression profile test can classify lesions as benign, intermediate-risk, or malignant, with a reported accuracy of 96.6%. The test aims to enhance diagnostic clarity, potentially impacting patient treatment decisions significantly. With approximately 300,000 challenging cases yearly in the U.S., this innovation could improve patient outcomes and reduce melanoma-specific mortality risks.
Castle Biosciences (Nasdaq: CSTL) announced its participation in the ASDP 57th Virtual Annual Meeting, showcasing two significant poster presentations. The presentations include DecisionDx®-Melanoma, focusing on predictors of sentinel lymph node metastasis, and DecisionDx® DiffDx™-Melanoma, which discusses a diagnostic gene expression profile for challenging pigmented lesions. Both presentations are set for November 9 and 10, 2020, highlighting the company's commitment to advancing skin cancer diagnostics through genomic testing.
Castle Biosciences (Nasdaq: CSTL) is set to release its third-quarter financial results on November 9, 2020. The results will be available after market close, followed by a conference call and webcast at 4:30 PM ET. The company specializes in skin cancer diagnostics, providing genomic information to enhance treatment decisions. Additionally, Castle offers tests for various melanomas and is developing solutions for other cancers.
Castle Biosciences, Inc. (Nasdaq: CSTL) has announced an investor webcast scheduled for Oct. 28, 2020, at 4:30 p.m. ET to discuss the launch of its ConfirmDx®-Melanoma test, set to be available in Q4 2020. This test aims to help dermatopathologists classify difficult-to-diagnose pigmented lesions, as approximately 300,000 of 2 million biopsied annually in the U.S. present diagnostic challenges. The webcast will feature guest speaker Dr. Sarah I. Estrada, along with a Q&A session.
Castle Biosciences (Nasdaq: CSTL) presented data on DecisionDx®-Melanoma at the 16th EADO Congress, demonstrating its ability to identify patients with T1-T2 melanoma at low risk of sentinel lymph node (SLN) positivity. In a study involving 2,303 patients, only 1.8% of low-risk patients over 65 had positive SLN results, compared to 14.6% in high-risk individuals. This test, validated in over 5,700 samples, aids in sparing patients unnecessary SLNB surgeries, potentially lowering healthcare costs. Recent Medicare coverage expansion for this test underscores its significance.
Castle Biosciences, Inc. (CSTL) highlighted its innovative tests during the 2020 ASDS Virtual Annual Meeting, showcasing findings on DecisionDx-Melanoma and DecisionDx-SCC. The DecisionDx-Melanoma test indicated that 69% of melanoma patients could avoid sentinel lymph node biopsies with a Class 1A result, boasting a 98% five-year survival predictive value. Additionally, DecisionDx-SCC demonstrated strong prognostic capabilities, stratifying patients into risk classes with significant survival differences: 93.9% for low risk, compared to 47.8% for high risk. These tests aim to enhance personalized cancer treatment approaches.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that Palmetto GBA MolDx issued a final expanded local coverage determination for its DecisionDx®-Melanoma test, effective Nov. 22, 2020. This gene expression profile test predicts the risk of metastasis and recurrence in melanoma patients, having been studied in over 5,700 samples. CEO Derek Maetzold expressed satisfaction over the expanded coverage, which enhances access for Medicare beneficiaries. The company continues to support the test's clinical utility with 26 peer-reviewed publications.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its participation in the 2020 ASDS Virtual Annual Meeting, where it will present data on its genomic tests for skin cancer. Notable presentations include:
- Clinical validation of a 40-gene test for cSCC by Sherrif Ibrahim, M.D., Ph.D., on October 9, 2020.
- Prognostic model combining a 31-gene test with sentinel lymph node biopsy by Aaron Farberg, M.D., also on October 9, 2020.
The presentations will be available for registrants for 30 days post-meeting.